Long term experience of one center with targeted therapies consisting of imatinib mesylate and sunitinib malate in patients with unresectable or metastatic KIT positive gastrointestinal stromal tumors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F15%3A%230000694" target="_blank" >RIV/00209805:_____/15:#0000694 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=4186&category_id=118&option=com_virtuemart&vmcchk=1&Itemid=1" target="_blank" >http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=4186&category_id=118&option=com_virtuemart&vmcchk=1&Itemid=1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/BLL_2015_042" target="_blank" >10.4149/BLL_2015_042</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Long term experience of one center with targeted therapies consisting of imatinib mesylate and sunitinib malate in patients with unresectable or metastatic KIT positive gastrointestinal stromal tumors

Popis výsledku v původním jazyce

A retrospective analysis of consecutive patients (183 in total, of which 105 were males and 78 females) with gastrointestinal stoma! tumour (GIST) was performed. The mean age was 61 years, median age 64 years. The most frequent localization of the tumour was stomach in 74 patients (40.4 %) and the small intestine in 46 patients (25.1 %). Two or more different synchronous or metachronous cancers occurred in 34 (18.6 %) patients with histologically confirmed GIST. Ninety-six patients were treated with imatinib mesylate in palliative setting during the course of their disease. The therapy was finished in 60 patients and 36 patients have been treated so far. The median progression-free survival reached 32.9 months in the group of 96 patients treated with imatinib. The median overall survival in the group of 96 patients treated for metastatic disease reached 77 months. Two-year and 5-year survival was 85.2 % and 63.1 %, respectively. The second-line therapy with sunitinib malate was administered in 37 patients, of which 31 finished and 6 continued in the therapy. The median progression free survival and median survival since the sunitinib therapy initiation reached 8.4 and 22.1 months, respectively (Tab. 2, Fig. 2, Ref. 16).

Název v anglickém jazyce

Long term experience of one center with targeted therapies consisting of imatinib mesylate and sunitinib malate in patients with unresectable or metastatic KIT positive gastrointestinal stromal tumors

Popis výsledku anglicky

A retrospective analysis of consecutive patients (183 in total, of which 105 were males and 78 females) with gastrointestinal stoma! tumour (GIST) was performed. The mean age was 61 years, median age 64 years. The most frequent localization of the tumour was stomach in 74 patients (40.4 %) and the small intestine in 46 patients (25.1 %). Two or more different synchronous or metachronous cancers occurred in 34 (18.6 %) patients with histologically confirmed GIST. Ninety-six patients were treated with imatinib mesylate in palliative setting during the course of their disease. The therapy was finished in 60 patients and 36 patients have been treated so far. The median progression-free survival reached 32.9 months in the group of 96 patients treated with imatinib. The median overall survival in the group of 96 patients treated for metastatic disease reached 77 months. Two-year and 5-year survival was 85.2 % and 63.1 %, respectively. The second-line therapy with sunitinib malate was administered in 37 patients, of which 31 finished and 6 continued in the therapy. The median progression free survival and median survival since the sunitinib therapy initiation reached 8.4 and 22.1 months, respectively (Tab. 2, Fig. 2, Ref. 16).

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bratislava medical journal-Bratislavské lekárske listy

ISSN

0006-9248

e-ISSN

—

Svazek periodika

116

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

4

Strana od-do

218-221

Kód UT WoS článku

000351975100002

EID výsledku v databázi Scopus

2-s2.0-84940106653